Company
Thalia Therapeutics plc
LON:N4P
Thalia Therapeutics is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The company is focused on unlocking the full therapeutic potential of RNA by overcoming the fundamental challenges of delivery, enabling targeted, scalable and clinically meaningful medicines for patients with significant unmet medical needs.
42 stories
Archive
Mobile Streams higher after launch of Pumas football club NFTs
A look at the major movers on the London market on Tuesday
Archive
Tintra climbs after short but dramatic update
A look at the major movers on the London market on Friday
Archive
Fevertree shares bubble up after rise in off-trade sales during lockdown
A look at the major movers on the London market on Thursday
Archive
Dillistone's solid start to the year blown off course
A look at some of the major movers in London on Thursday
N4 Pharma builds understanding of Nuvec as it looks towards clinical trials
Lab work in both in vitro and in vivo studies and an oncology efficacy model will be the next steps.
TechFinancials shares push higher after launch of blockchain diamond exchange
A look at some winners and losers in the UK equity market on Wednesday
N4 Pharma surges as MedImmune agrees to extend collaboration deal
The two parties had been working together as part of a project funded by the UK government and they have agreed to continue their research
N4 Pharma surges on latest Nuvec study data
N4 Pharma has shown that Nuvec not only delivers DNA directly into cells, but that it does so to a sufficient level to generate an immune response
N4 Pharma’s Nuvec delivery system gets free shot in arm
Nuvec has been accepted by the European Nanomedicine Characterisation Laboratory (EUNCL) to undertake a full characterisation programme
Investments and investor services
Market movers: N4 Pharma gets boost from the Men (and women) from EUNCL; Zinc Media surges after bagging several commissions
A look at the day's movers and shakers, featuring N4 Pharma, Zin Media, Rurelec, Trinity Exploration, Hurricane Energy, Thomas Cook, Gama Aviation, CyanConnode and Mosman
N4 Pharma heads down on disappointing data from Viagra reformulation study
The full set of results haven’t been made available yet, but N4 told investors that “it is clear” from the initial data that its reformulation did not have the desired effect on ED sufferers
Logistics group Xpediator to raise £7mln to fund acquisition of Import Services Limited
Some of the main news driven risers and fallers on Monday afternoon ...
N4 Pharma heads down on disappointing data from Viagra reformulation study
The full set of results haven’t been made available yet, but N4 told investors that “it is clear” from the initial data that its reformulation did not have the desired effect on ED sufferers
Archive
"Mindless momentum" strategy not working for small caps
Stockpot is running three virtual portfolios based on the idea of momentum investing - investing in stocks that are rising sharply. Next week, we will look at how the big caps and mid-caps did but this week we look at the horror story that
N4 Pharma on the rise as it files patent application for premature ejaculation drug
The drug is an oral reformulation of an anti-depressant, but N4 says studies have shown it has “promise” as a treatment for premature ejaculation
Archive
Momentum investing: Use the Force, Luke
A lot of academic research suggests a momentum investing strategy outperforms the market. John Harrington attempts to concoct a lazy person's momentum investing system.
Westminster Group top London riser on Middle East opportunity update
Proactive takes a look at what's moving on a half day of London trading
Investments and investor services
Parallel Media and Physiomics lead small cap market gainers
Some of the biggest risers and fallers in London on Wednesday
Galileo Resources soars higher as initial drilling at Concordia copper project completed
A look at some of the biggest London-listed risers and fallers today